A systems-level operator across product, technology, and commercial — with a growth-equity exit behind me. One through-line: durability.
Engagements usually start small — a single diligence read, or a half-day with a portfolio company's product leadership — and grow from there if they're useful.
Reading a target's product and technology the way the Durability Stack reads a moat: what's genuinely defensible, what the customer or a competitor can reclaim, where the real AI exposure sits — past the surface "it's SaaS, so it's exposed" read.
One example of what that surfaces: almost no vendor today can show which work was done by an AI agent and who is accountable for it. It scores nothing in a feature comparison, so it appears on no scorecard — and it becomes a priced gap at exit. That's the class of finding a durability read is looking for.
A standing sounding board to the fund on product and technology, across pipeline and portfolio.
Working directly with portfolio-company product and tech leaders on CPTO-level strategy where a fund wants hands-on support, not a report.
Regular consultations through expert networks, usually M&A-driven. Where the technology actually stands, how the vendor landscape is really shaped, which players are stronger or weaker than the market assumes.
A peer who's held the seat — CTO first, then CPO / CPTO — and been through the exit, bringing the investor's-eye view back to the operator's side of the table.
A formal seat with a scale-up, bringing product, technology, and commercial judgment.
A senior peer to pressure-test product and technology strategy with — for a CPO, CPTO, or a CEO carrying product.
Helping a leadership team make their durability legible before investors stress-test it.
I read product, technology, and the commercial logic connecting them. I don't run code, security, or infrastructure audits — a full technical DD needs a specialist alongside me, and I'll say so early rather than late.
My regulated-industry depth is European mid-market EHS, ESG, and quality and integrated management systems. The pharma and medical-device end of quality management — where systems have to be formally validated — is the adjacent neighbourhood, not mine.
I'm European. On US-market questions I'm a second opinion, not a first.
Worth a conversation?
Email is fastest. LinkedIn if you'd rather check the background first.